---
title: "Machine Learning–Defined LUAD Subtypes and RRM2 Linked to Cisplatin Resistance"
id: "pubmed-42958928"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42958928"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42958928/"
doi: "10.1111/1759-7714.70407"
published_at: "2026-11-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Machine Learning–Defined LUAD Subtypes and RRM2 Linked to Cisplatin Resistance
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42958928
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42958928/)
- **DOI:** [10.1111/1759-7714.70407](https://doi.org/10.1111%2F1759-7714.70407)
- **Published At:** 2026-11-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The investigators used multi‑omics integration and a suite of clustering approaches to define two molecular subtypes of **LUAD**. - A consensus machine learning–derived signature (CMLS) was generated from iterative modeling across many algorithms; the source reported 19 genes in the final signature. - Patients in Cluster A had better survival and greater immune activation compared with the other subtype, based on Kaplan–Meier and pathway activity analyses. - The CMLS stratified patients: high CMLS scores associated with lower CD4+ T‑cell infiltration, worse survival, and weaker immunotherapy responses; low scores had an immunologically “hot” phenotype and better outcomes. - The study team identified **RRM2** (ribonucleotide reductase subunit M2) as a core prognostic regulator upregulated in lung cancer tissues and LUAD cell lines. - Functional assays reported that suppression of **RRM2** increased cisplatin (DDP) sensitivity in an A549/DDP cell model; the article linked **RRM2** to **cisplatin** resistance. - Model performance was evaluated using concordance metrics across TCGA‑LUAD and external GEO cohorts (META‑LUAD: GSE50081 and GSE37745); models were ranked by average C‑index across validation sets. - Hub gene selection used a survival SVM algorithm; univariate Cox regression analyses were presented for hub genes across training and validation cohorts. - The authors provided immunohistochemistry and Western blot evidence for elevated **RRM2** protein in tumor samples and cell lines relative to controls. - The source did not report specific dosing regimens, patient-level demographics, or randomized clinical endpoints; those details were not provided in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42958928/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42958928%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42958928/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42958928/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42958928/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42958928/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42958928/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42958928/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42958928%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42958928%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42958928/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42958928/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42958928/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42958928/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42958928/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42958928/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42958928/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42958928/#conflict-of-interest) * [ Figures ](https://pubmed.ncbi.nlm.nih.gov/42958928/#figures) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42958928/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42958928/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42958928/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42958928/#grants) Title & authors Abstract Conflict of interest statement Figures References MeSH terms Substances Grants and funding Thorac Cancer Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Thorac+Cancer%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Thorac+Cancer%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42958928/) . 2026 Nov;17(21):e70407. doi: 10.1111/1759-7714.70407. # Integrating Machine Learning to Identify Prognostic Subtypes and the Cisplatin Resistance Gene RRM2 in Lung Adenocarcinoma [Huirong Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+H&cauthor_id=42958928)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-1 "Department of Pulmonary and Critical Care Medicine, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Ting Tao](https://pubmed.ncbi.nlm.nih.gov/?term=Tao+T&cauthor_id=42958928)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-3 "Department of Nephrology, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongging, China."), [Zhenqing Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+Z&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Kerong Zhai](https://pubmed.ncbi.nlm.nih.gov/?term=Zhai+K&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Baiqiang Cui](https://pubmed.ncbi.nlm.nih.gov/?term=Cui+B&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Haiming Feng](https://pubmed.ncbi.nlm.nih.gov/?term=Feng+H&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Peiqiang Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+P&cauthor_id=42958928)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-4 "Department of Genetics, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu Province, China."), [Bin Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+B&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#full-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China.") Affiliations Expand ### Affiliations * 1 Department of Pulmonary and Critical Care Medicine, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China. * 2 Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China. * 3 Department of Nephrology, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongging, China. * 4 Department of Genetics, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu Province, China. * PMID: **42958928** * PMCID: [ PMC13720667 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13720667/) * DOI: [ 10.1111/1759-7714.70407 ](https://doi.org/10.1111/1759-7714.70407) Item in Clipboard # Integrating Machine Learning to Identify Prognostic Subtypes and the Cisplatin Resistance Gene RRM2 in Lung Adenocarcinoma Huirong Huang et al. Thorac Cancer. 2026 Nov. Show details Display options Display options Format Abstract PubMed PMID Thorac Cancer Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Thorac+Cancer%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Thorac+Cancer%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42958928/) . 2026 Nov;17(21):e70407. doi: 10.1111/1759-7714.70407. ### Authors [Huirong Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+H&cauthor_id=42958928)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-1 "Department of Pulmonary and Critical Care Medicine, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Ting Tao](https://pubmed.ncbi.nlm.nih.gov/?term=Tao+T&cauthor_id=42958928)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-3 "Department of Nephrology, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongging, China."), [Zhenqing Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+Z&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Kerong Zhai](https://pubmed.ncbi.nlm.nih.gov/?term=Zhai+K&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Baiqiang Cui](https://pubmed.ncbi.nlm.nih.gov/?term=Cui+B&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Haiming Feng](https://pubmed.ncbi.nlm.nih.gov/?term=Feng+H&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China."), [Peiqiang Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+P&cauthor_id=42958928)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-4 "Department of Genetics, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu Province, China."), [Bin Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+B&cauthor_id=42958928)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42958928/#short-view-affiliation-2 "Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China.") ### Affiliations * 1 Department of Pulmonary and Critical Care Medicine, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China. * 2 Department of Thoracic Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China. * 3 Department of Nephrology, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongging, China. * 4 Department of Genetics, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu Province, China. * PMID: **42958928** * PMCID: [ PMC13720667 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13720667/) * DOI: [ 10.1111/1759-7714.70407 ](https://doi.org/10.1111/1759-7714.70407) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Lung adenocarcinoma (LUAD) is a highly invasive malignancy associated with poor prognosis. However, reliable molecular subtypes and prognostic signatures for LUAD, particularly their associations with tumor immunity and treatment response, remain poorly characterized. This study aimed to identify distinct molecular subtypes and establish a robust prognostic signature for LUAD, while exploring potential therapeutic targets associated with cisplatin resistance. In this study, we integrated ten clustering algorithms with 101 machine learning methods to identify two distinct molecular subtypes of LUAD and established a robust consensus machine learning-derived signature (CMLS). Patients belonging to the Cluster A subtype exhibited a more favorable prognosis and an enhanced immune response. Furthermore, a CMLS model constructed from 19 genes exhibited strong predictive power. Individuals with high CMLS scores displayed reduced CD4 + T-cell infiltration, poorer survival outcomes, and diminished responses to immunotherapy, whereas those with the low CMLS scores showed improved clinical outcomes, better immunotherapy responsiveness, and features of an immunologically "hot" tumor phenotype. Among the identified genes, ribonucleotide reductase subunit M2 (RRM2) emerged as a core regulator associated with LUAD prognosis. RRM2 was markedly upregulated in lung cancer tissues and the LUAD cell lines and was associated with the cisplatin (DDP) resistance. Suppression of RRM2 expression significantly enhanced the cisplatin sensitivity of A549/DDP cells. In summary, our findings establish a molecular classifier that stratifies LUAD patients into distinct risk categories and highlight RRM2 as a promising biomarker and therapeutic target associated with cisplatin resistance. **Keywords:** Muti‐omics; RRM2; cisplatin resistance; lung adenocarcinoma; machine learning; molecular subtypes; prognosis. © 2026 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement The authors declare no conflicts of interest. ## Figures [ ![FIGURE 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/7183a70a30da/TCA-17-e70407-g002.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/79d45872ea12/TCA-17-e70407-g002.webp) ** FIGURE 1 ** Identification and characterization of two… ** FIGURE 1 ** Identification and characterization of two molecular subtypes in LUAD via multi‐omics integration. (A)… **FIGURE 1** Identification and characterization of two molecular subtypes in LUAD via multi‐omics integration. (A) Determination of the optimal number of clusters using the Cluster Prediction Index (CPI) and gap statistics. (B) Consensus matrix derived from ten clustering algorithms, showing stable classification into two subtypes. (C) Heatmap illustrating the multi‐omics landscape of gene expression (11 706 genes) and 50 hallmark pathway scores across the two molecular subtypes. (D) Silhouette analysis validating the separation and cohesion of the two identified subtypes. (E) Kaplan–Meier survival analysis comparing the prognostic outcomes of the two subtypes. (F) Heatmap of differentially expressed genes (DEGs) between the two subtypes. (G) Heatmap of the 50 hallmark pathway activity scores, highlighting differential enrichment between the two subtypes. [ ![FIGURE 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/6e1c8c9dcf0a/TCA-17-e70407-g004.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/930d4dcb68ef/TCA-17-e70407-g004.webp) ** FIGURE 2 ** The generation and prognostic value… ** FIGURE 2 ** The generation and prognostic value of CMLS. (A) A robust computational framework was… **FIGURE 2** The generation and prognostic value of CMLS. (A) A robust computational framework was employed to construct 101 machine learning models. Model performance was assessed via the concordance index (C‐index) using both the TCGA‐LUAD and META‐LUAD (GSE50081 and GSE37745) cohorts, and models were ranked based on the average C‐index across validation sets. (B) Hub gene selection was carried out using the survival SVM algorithm. (C) Summary of univariate Cox regression analyses for hub genes in both training and validation cohorts. (D–F) Kaplan–Meier survival curves comparing high versus low CMLS groups in the TCGA‐LUAD and META‐LUAD (GSE50081 and GSE37745) cohorts, respectively. [ ![FIGURE 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/c02348c5a1bc/TCA-17-e70407-g009.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/8445af614e43/TCA-17-e70407-g009.webp) ** FIGURE 3 ** Analysis of Prognostic Genes. (A)… ** FIGURE 3 ** Analysis of Prognostic Genes. (A) Variable importance plot derived from the out‐of‐bag data.… **FIGURE 3** Analysis of Prognostic Genes. (A) Variable importance plot derived from the out‐of‐bag data. (B) The model error rate across the number of grown trees. (C) Western blot analysis shows RRM2 protein expression in five LUAD cell lines compared to the BEAS‐2B normal bronchial epithelial cell line. (D) Immunohistochemical analysis of RRM2 expression in representative tissue sections. **_p_ < 0.01, ***_p_ < 0.001, ****_p_ < 0.0001. [ ![FIGURE 4](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/d27b4ea42b47/TCA-17-e70407-g007.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/13720667/a964b1486e7a/TCA-17-e70407-g007.webp) ** FIGURE 4 ** Evaluation of the prognostic performance… ** FIGURE 4 ** Evaluation of the prognostic performance and clinical utility of the CMLS. (A–C) Benchmarking… **FIGURE 4** Evaluation of the prognostic performance and clinical utility of the CMLS. (A–C) Benchmarking analysis comparing the performance of the CMLS model against previously published signatures in the TCGA‐LUAD and META‐LUAD (GSE50081 and GSE37745) cohorts. (D) Web‐based interactive nomogram for the CMLS. (E) Decision curve analysis of the CMLS nomogram. (F, G) Univariable and multivariable Cox regression
## Related Clinical Research

- [FFAR1 and FFAR4 Signaling Modulates Fibroblast Responsiveness in Highly Invasive Lung Cancer Cells](https://medichelpline.com/clinical-feed/pubmed-42934337.md) (DOI: 10.1007/s00418-026-02553-y)
- [TRPV1-targeted Fe-phenolate (FeOLDA) induces apoptosis and ferroptosis in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42411334.md) (DOI: 10.1039/d6bm00434b)
- [Pollen size shifts after whole genome duplication in autotetraploids](https://medichelpline.com/clinical-feed/biorxiv-17-biased-evolution-of-pollen-size-after-whole-genome-duplication.md)
- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.